WHO and Gilead advance HIV prevention with new injectable options and global funding efforts

The WHO recommends the use of the long-acting HIV prevention injection lenacapavir, approved in the US for twice-yearly use, as part of global efforts to combat HIV, especially in high-risk groups. Despite its potential, funding cuts, particularly from the US, threaten to undermine HIV prevention programs worldwide, risking increased infections and deaths. Gilead Sciences has committed to supplying lenacapavir at no profit to improve access in low-income countries, but global resource gaps remain a major challenge in ending the HIV epidemic.